Insiders who reported open-market trades in the last 12 months at the companies Daniel Karlin files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Robert Barrow - $3.98M in DFTX purchases and sales in the last 12 months
Mark Sullivan - $1.45M in DFTX purchases and sales in the last 12 months
Brandi Roberts - $259K in DFTX purchases and sales in the last 12 months
Matthew T. Wiley - $242K in DFTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Daniel Karlin is a corporate insider, tracked as Chief Medical Officer, Director of Definium Therapeutics, Inc. (DFTX). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Daniel Karlin submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Daniel Karlin been buying or selling stock?
Recorded transactions: 0 open-market purchases and 6 open-market sales ($1.20M) across all tracked filings.
Daniel Karlin is Chief Medical Officer, Director of Definium Therapeutics, Inc. (DFTX). 10 SEC Form 4 filings on record going back to 2024, most recently on 30 September 2026. Most recent open-market trade: sold $397K of DFTX on 30 September 2026. Lifetime open-market sales: $1.20M.
Recent transactions
10
The latest 10 SEC Form 4 transactions reported by Daniel Karlin.
InsiderAlpha's records for Daniel Karlin go back to 2024: 10 primary Form 4 filings, an average of 3.3 per year. 5 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
